Vertex Q3 revenue climbs 12% to $3.44bn as guidance increases
Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter 2026 revenue of $3.44 billion, up 12% year over year, and raised its full-year revenue guidance to $13.15 billion–$13.25 billion.























